API Product   :    Indacaterol Maleate
CEP   :    -
WCC   :    -
Therapeutic Use    :    Chronic Obstructive Pulmonary Disease(COPD)
Originator   :    Novartis
CAS No.    :    312753-06-3
Trade Name.   :    Onbrez, Arcapta
Molecular Weight   :    392.490 g/mol
Molecular Formula   :    C24H28N2O3
Indacaterol is used to treat trouble breathing and wheezing due to a certain ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and/or emphysema). It is used if your breathing problems are not controlled with other medication (such as a quick-relief inhaler).
Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009,[2] and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011.[3] It needs to be taken only once a day,[4] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.